These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37118754)

  • 21. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
    Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
    Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
    Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
    Bauer AH; Erly W; Moser FG; Maya M; Nael K
    Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
    Li M; Tang H; Chan MD; Zhou X; Qian X
    Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
    Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma.
    Park KJ; Kim HS; Park JE; Shim WH; Kim SJ; Smith SA
    Eur Radiol; 2016 Dec; 26(12):4390-4403. PubMed ID: 26883333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma.
    Kim M; Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH
    Eur Radiol; 2021 Aug; 31(8):6374-6383. PubMed ID: 33569615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
    El-Abtah ME; Talati P; Fu M; Chun B; Clark P; Peters A; Ranasinghe A; He J; Rapalino O; Batchelor TT; Gilberto Gonzalez R; Curry WT; Dietrich J; Gerstner ER; Ratai EM
    Neurooncol Adv; 2022; 4(1):vdac128. PubMed ID: 36071927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression.
    Roques M; Catalaa I; Raveneau M; Attal J; Siegfried A; Darcourt J; Cognard C; de Champfleur NM; Bonneville F
    PLoS One; 2022; 17(10):e0270216. PubMed ID: 36227862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
    Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
    Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.
    Elshafeey N; Kotrotsou A; Hassan A; Elshafei N; Hassan I; Ahmed S; Abrol S; Agarwal A; El Salek K; Bergamaschi S; Acharya J; Moron FE; Law M; Fuller GN; Huse JT; Zinn PO; Colen RR
    Nat Commun; 2019 Jul; 10(1):3170. PubMed ID: 31320621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
    Bonm AV; Ritterbusch R; Throckmorton P; Graber JJ
    J Neuroimaging; 2020 Mar; 30(2):139-145. PubMed ID: 31925884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective examination of pseudoprogression in
    Wetzel EA; Farrell MJ; Eldred BSC; Liu V; Saha I; Zapanta Rinonos S; Prins T; Li T; Cao M; Hegde J; Kaprealian T; Khanlou N; Liau LM; Nghiemphu PL; Cloughesy TF; Chong RA; Ellingson BM; Lai A
    Neurooncol Adv; 2023; 5(1):vdad028. PubMed ID: 37128507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
    Kong DS; Kim ST; Kim EH; Lim DH; Kim WS; Suh YL; Lee JI; Park K; Kim JH; Nam DH
    AJNR Am J Neuroradiol; 2011 Feb; 32(2):382-7. PubMed ID: 21252041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
    Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
    Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.